Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Y2k_fan who wrote (1009)	6/1/1998 10:01:00 PM
From: Jeffrey L. Henken	Read Replies (3) \| Respond to of 2887

Economic Impact Of FDA Latex Allergies Labeling Update An Excerpt: fda.gov In the Federal Register of September 30, 1997 (62 FR 51021), FDA published a final rule (to be codified at 21 CFR 801.437), under its authority in section 505(a) and (f) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352(a) and (f)), requiring certain labeling statements on medical devices that contain or have packaging that contains natural rubber. This rule becomes effective on September 30, 1998. The agency issued this rule because medical devices composed of natural rubber may pose a significant health risk to some consumers and health care providers who are sensitized to natural latex proteins. The FDA has received numerous reports about adverse effects related to reactions to natural latex proteins contained in medical devices, including 16 deaths following barium enemas. These deaths were associated with anaphylactic reactions to the natural rubber latex cuff on the tip of barium enema catheters. Scientific studies and case reports have documented sensitivity to natural latex proteins found in a wide range of medical devices. It is estimated that 5 to 17 percent of health care workers are sensitive to latex proteins(Refs. 1 through 5). It isn't all worth reading but the facts are simple. Latex allergies are not going away and neither am I. GO ABMI Regards, Jeff

To: Y2k_fan who wrote (1009)	7/23/1998 12:01:00 PM
From: Jeffrey L. Henken	Read Replies (1) \| Respond to of 2887

American BioMed will be bringing the OmniFilter to market next year. The market for this device in the US alone could be as much as $500 million a year. This carotid artery filter could be used to help remove the plaque that breaks loose during surgery to open a constricted area of the carotid artery. Strokes are the third leading cause of death in the United States and carotid artery occlusion is the leading cause of strokes. AMBI has what a hope will be a terrific patented product here in the OmniFilter: americanbiomed.com The carotid artery runs through the neck, branching to the face and brain. In people with atherosclerosis, fatty deposits may build up at the branch point -- the place where you feel your pulse. With time, the deposits may block the artery completely or a piece of plaque may break off and lodge in the brain. The result is a stroke, which kills brain cells by depriving them of oxygen and nutrients. The dying cells then wreak havoc on surrounding parts of the brain. Stroke is the leading cause of long-term disability in industrialized countries, accounting for the lingering symptoms of 2 to 3 million people in the United States. It also kills half a million Americans each year, and carotid artery disease is thought to be the cause 20 to 30 percent of the time. Regards, Jeff